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Abstract 6-Fluoro-(18F)-L-3,4-dihydroxyphenylalanine
(FDOPA) is an amino acid analogue for positron emission
tomography (PET) imaging which has been registered since
2006 in several European Union (EU) countries and by
several pharmaceutical firms. Neuroendocrine tumour
(NET) imaging is part of its registered indications. NET
functional imaging is a very competitive niche, competitors
of FDOPA being two well-established radiopharmaceuticals
for scintigraphy, 123I-metaiodobenzylguanidine (MIBG) and
111In-pentetreotide, and even more radiopharmaceuticals for
PET, including fluorodeoxyglucose (FDG) and somatostatin
analogues. Nevertheless, there is no universal single photon
emission computed tomography (SPECT) or PET tracer for
NET imaging, at least for the moment. FDOPA, as the other
PET tracers, is superior in diagnostic performance in a
limited number of precise NET types which are currently
medullary thyroid cancer, catecholamine-producing
tumours with a low aggressiveness and well-differentiated
carcinoid tumours of the midgut, and in cases of congenital
hyperinsulinism. This article reports on diagnostic
performance and impact on management of FDOPA accord-
ing to the NET type, emphasising the results of comparative
studies with other radiopharmaceuticals. By pooling the
results of the published studies with a defined standard of
truth, patient-based sensitivity to detect recurrent medullary
thyroid cancer was 70 % [95 % confidence interval (CI)
62.1–77.6] for FDOPAvs 44 % (95 % CI 35–53.4) for FDG;
patient-based sensitivity to detect phaeochromocytoma/par-
aganglioma was 94 % (95 % CI 91.4–97.1) for FDOPA vs
69 % (95 % CI 60.2–77.1) for 123I-MIBG; and patient-based
sensitivity to detect midgut NET was 89 % (95 % CI 80.3–
95.3) for FDOPA vs 80 % (95 % CI 69.2–88.4) for somato-
statin receptor scintigraphy with a larger gap in lesion-based
sensitivity (97 vs 49 %). Previously unpublished FDOPA
results from our team are reported in some rare NET, such as
small cell prostate cancer, or in emerging indications, such
as metastatic NET of unknown primary (CUP-NET) or
adrenocorticotropic hormone (ACTH) ectopic production.
An evidence-based strategy in NET functional imaging is
as yet affected by a low number of comparative studies.
Then the suggested diagnostic trees, being a consequence of
the analysis of present data, could be modified, for some
indications, by a wider experience mainly involving face-to-
face studies comparing FDOPA and 68Ga-labelled peptides.
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Neuroendocrine tumours (NET) are derived from endocrine
cells; they usually contain secretory granules and have the
capacity to produce biogenic amines and polypeptide hor-
mones. These tumours often pose a difficult diagnostic
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challenge because of their small size and multiplicity. Nev-
ertheless, an accurate staging of NET is important for the
determination of resectability and of the prognosis. In 156
NET patients with the gastroenteropancreatic (GEP) type,
the 5-year survival rate was lower (50 %) in 20 patients with
extrahepatic secondary lesions than in 61 patients with only
hepatic metastases (73 %) or 18 patients with nodal involve-
ment (77 %) or in those with only local disease (96 %) [1].
The presence of extrahepatic sites of disease, bone metasta-
ses in particular, has been suggested to be a marker of a
subgroup of patients with a worse prognosis and shorter
survival [2] who would benefit more from aggressive ther-
apeutic approaches.
Somatostatin receptor scintigraphy (SRS) with single
photon emission computed tomography (SPECT), using
111In-pentetreotide or another somatostatin analogue la-
belled with 99mTc, detects the presence of somatostatin
receptors, mainly the subtype 2. SRS is still currently the
reference nuclear medicine investigation in NET. Being a
whole-body examination, it is convenient for staging, with
drawbacks linked to its biodistribution: a high activity in the
liver, the spleen and delayed gut activity due to biliary
excretion. SRS also has a clear limitation due to its poor
spatial resolution to characterise suspicious lesions smaller
than 10 mm on anatomic imaging modalities or to discover
unsuspected small-sized lesions. Another cause of false-
negative results is a lack of somatostatin receptor subtype
2 on the tumour tissue. In contrast, it has the advantage,
when positive, to predict response to somatostatin analogue
treatment [3].
An alternative to SRS is metaiodobenzylguanidine
(MIBG) scintigraphy and SPECT, which is almost exclu-
sively used in NET for imaging phaeochromocytomas, che-
modectomas and rarely some NET of the ileum or medullary
thyroid cancer (MTC). 123I or 131I have been both used for
MIBG scintigraphy, but 123I-MIBG yields images with bet-
ter resolution and a better signal for SPECT(/CT) and is
currently the most widely reported for diagnostic
application.
To take advantage of the superior resolution and the
accurate uptake quantification offered by positron emis-
sion tomography (PET), several tracers have been pro-
posed for a more effective functional imaging of NET.
Currently, the only one that obtained a marketing
authorisation (MA) in the European Union (EU) explic-
itly mentioning NET is 6-fluoro-(18F)-L-3,4-dihydroxy-
phenylalanine (FDOPA). Other “specific” NET tracers
such as 6-fluoro-(18)-fluorodopamine (FDA) or the sero-
tonin precursor 5-hydroxytryptophan (5-HTP) labelled
with 11C have been proposed as well as several somato-
statin analogues labelled with positron-emitting radionu-
clides, 68Ga in most cases (SRPET or SRPET/CT on
hybrid PET/CT machines).
Importantly, poorly differentiated neuroendocrine can-
cers with little or no hormone production and a high prolif-
erative activity usually take up 18F-fluorodeoxyglucose
(FDG) as do most “common” cancers [4, 5], while sensitiv-
ity of NET tracers is poor.
FDOPA vs other radiopharmaceuticals
FDOPA has been used for PET imaging in humans for more
than two decades, initially for studying the physiology and
physiopathology of dihydroxyphenylalanine (DOPA) bio-
distribution in the human brain, in particular Parkinson’s
syndrome, and then in oncology for NET or brain tumours.
The pathophysiological rationale for PET imaging of NET
with FDOPA is that several types of NET tumours are able
to take up, decarboxylate and store amino acids, such as
DOPA, and their biogenic amines [6, 7]. MAwas granted for
a commercial preparation of FDOPA in France in 2006, and
others since then; and this radiopharmaceutical is commer-
cially available.
Of the radiopharmaceuticals which are authorised by the
French medicines agency for use in this context in our
department, the least expensive is 18F-FDG, followed by
123I-MIBG, then 68Ga-edotreotide (68Ga-DOTATOC) and
111In-pentetreotide, 18F-FDOPA being the most expensive.
This is due to a complicated process of 18F-FDOPA label-
ling which requires 18F2 gas instead of
18F-fluoride ion and
has a low yield. However, the cost of the whole imaging
examination integrates many other factors such as the time
spent by the radiopharmacist and the technologist for the on-
site preparation of the injection, the longest for DOTATOC,
and the duration of the image acquisition, far longer with
SPECT than with PET, impacting on the cost of the personnel
and the workflow of the machine. The cost of the multiple
transportations of the patient for the multiple scans which are
recommended with MIBG or SRS should be taken into ac-
count. All those factors clearly reduce the gap in cost between
FDOPA PET/CT, a rapid procedure, and SPECT/CT.
Furthermore, in the benefit-cost ratio, the benefit is not
equal for all those radiopharmaceuticals. As will be further
discussed in this article, the diagnostic performance of all
those radiopharmaceuticals differs according to the type of
the NET. A patient-based analysis of diagnostic performance
is important, in particular for the detection of residual tumour
after a radical treatment, but a lesion- or site-based analysis is
also important as evaluating the real extension of the disease is
a key element for tumour resectability and surgical procedure
with curative intent. The benefit, evaluated by the impact on
patient management, also depends on the potential use of
internal radiotherapy revealed by the imaging modality.
MIBG uptake by NET tumours may pave the way to 131I-
MIBG internal radiotherapy which had been granted MA for
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several years to target NETs as well as neuroblastoma, and
similarly a positive somatostatin analogue imaging opens
the option of internal radiotherapy with 90Y- or 177Lu-
labelled ligands of somatostatin receptors [8]. There is
no such direct link with FDOPA or FDG imaging. But
actually a radiopharmaceutical with a different functional
approach is an advantage for indicating and monitoring
internal radiotherapy: by comparing images of FDOPA
PET/CT and MIBG SPECT or SRPET, tumours only
taking up FDOPA can be delineated which are less likely
to respond to the planned radiotherapy or have resisted to
a past attempt, while the receptor-bearing tumours could
have responded, leading to false-negative results when
monitoring with the corresponding radiopharmaceutical.
FDOPA PET and PET/CT
The practice for FDOPA PET imaging in NET is not
fully standardised at the moment. A 4-h fast is recom-
mended by all teams, but sugar intake may be author-
ised in particular in hypoglycaemic patients. The oral
premedication with the decarboxylase inhibitor carbi-
dopa, which was introduced to block the aromatic ami-
no acid decarboxylase enzyme, is less common than for
brain FDOPA imaging. Eriksson et al. [9] reported that
this administration led to a sixfold decrease in renal
excretion while the tumour uptake increased threefold.
Concordantly, Timmers et al. [10] reported that, com-
pared with baseline FDOPA PET, carbidopa pretreat-
ment resulted in the detection of 3 additional lesions
in 3 of 11 patients with phaeochromocytoma or extra-
adrenal paraganglioma. In contrast, in one infant in the
series of Ribeiro et al. [11] the diffuse uptake of
FDOPA in the pancreas completely disappeared under
carbidopa treatment, while the kidney activity was still
present: the patient had histologically proven diffuse
abnormal pancreatic cells scattered in the whole pancre-
as. Similar findings were reported by Kauhanen et al. in
2008 in two of three adults with insulinoma. These
findings do not favour the use of carbidopa in patients
with pancreatic tumours since pancreatic physiological
uptake disappears, and tumour uptake could not also
disappear along with this [12].
The range of injected activity is 2–4 MBq/kg of body
mass according to the MA, typically 150–400 MBq, reflect-
ing the rapid evolution of PET machines, from 2-D acqui-
sition to 3-D and then time-of-flight acquisition, allowing a
reduction in injected activity. According to International
Commission on Radiological Protection (ICRP) 106 (2008
vol. 38), the effective dose after IV injection of 18-FDOPA is
0.025 mSv/MBq in adults and 0.10 mSv/MBq in a 1-year-
old child.
The FDOPA uptake by most organs and target lesions has
been described as a plateau between 30 and 90 min post-
injection [10]; there was no advantage of the 90-min scan
over the 30-min scan, visually or with determination of
standardized uptake value (SUV), in a series of 23 patients
with various NET [13]. Thus, the starting time of whole-
body image acquisition usually ranges between 45 and
65 min post-injection. However, early image acquisition
15–20 min after injection is useful in some indications, in
particular MTC [14] or phaeochromocytoma [15].
In cases of metastatic NET, FDOPA is taken up not only
by the soft tissue lesions but also by the bone metastases. In
a series of 23 patients with advanced stage NET, FDOPA
accurately detected skeletal lesions (sensitivity of 100 % and
specificity of 91 %), even in 40 % of patients with a
negative CT scan [13].
FDOPA PET is now performed on hybrid machines
which provide PET/CT fusion and increase diagnostic per-
formance. In a study comparing FDOPA PET/CT, PET or
CT alone in MTC [16], PET identified all 18 lesions as
positive, but was unable to definitively localise 4 lesions
(22 %); CT could localise all 18 lesions, but could not
definitively diagnose or exclude MTC in 6 lesions (33 %);
only FDOPA PET/CT accurately characterised and localised
all 18 lesions. Similar results demonstrating the superiority
of FDOPA PET/CT over FDOPA PET and CT alone have
been reported in phaeochromocytoma [17], midgut carci-
noid tumours or pancreatic islet cell tumours [18].
False-positive results in inflammatory lesions that are
frequent with FDG PET seem to be very rare with
FDOPA PET. There is in fact one single report in on-
cology published as an abstract [19]: on FDOPA PET
performed during treatment evaluation of a small cell
neuroendocrine laryngeal carcinoma, a mediastinal hot
spot corresponded to sarcoidosis. Nevertheless, the possi-
bility of an inflammatory lesion should be kept in mind
when an unexpected FDOPA focus is detected. The
physiological diffuse uptake in the pancreas, and in the
gallbladder leading to gut activity, may cause some prob-
lems in the interpretation.
As our team previously demonstrated by comparing
the uptake of several tracers, NET does not constitute a
biologically and metabolically homogeneous group of
tumours [20, 21]. We will thus report on the utility of
FDOPA by distinguishing the major types of NET and
emphasising recent comparative studies with other radio-
pharmaceuticals. An evidence-based strategy in NET
functional imaging is as yet affected by a low number
of comparative studies. Then the suggested diagnostic
trees, being a consequence of the analysis of present
data, could be modified, for some indications, by a wider
experience mainly involving face-to-face studies compar-
ing FDOPA and 68-labelled peptides.
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Medullary thyroid cancer
The initial study by Hoegerle et al. [22] compared, in 11
MTC patients, FDOPA PET with the established functional
and morphological imaging methods, including FDG PET.
A recent meta-analysis of eight studies on suspected recur-
rent MTC found the patient-based detection rate for FDOPA
PET(/CT) to be 66 and 71 % for lesion-based analysis,
which is an operational result in cases of occult recurrent
disease [23]. All published studies have confirmed the su-
periority of FDOPA over all other radiopharmaceuticals [16,
22, 24–32] (Table 1), in particular in the detection of meta-
static lymph nodes [22, 32] (Fig. 1). When compared to
morphological imaging, FDOPA has a clear advantage for
specificity [22, 29]. Pooling the results of three studies [26,
32, 33], the impact of FDOPA PET(/CT) estimated by the
rate of changes in patient management is 20/59 =34 %. The
performance of FDOPA varies according to the serum levels
of the two biochemical markers, calcitonin (CTN) and car-
cinoembryonic antigen (CEA).
In the comparative study by Koopmans et al. [27],
FDOPA was the most sensitive imaging modality, but of
eight patients with CTN <500 ng/l FDOPA was positive in
only one (CTN=86 ng/l, CEA=1.1 μg/l) and FDG in another
one (CTN =73 ng/l, CEA =1.2 μg/l). In the study of Luster
et al. [16], no true-positive FDOPA PET/CT case was found
in patients with basal CTN <60 ng/l, and conversely, no
true-negative PET/CT case was found in patients with basal
CTN >120 ng/l. FDOPA PET/CT had 100 % sensitivity and
specificity when CTN at the time of scanning was
>150 ng/l.
FDG may detect lesions missed by FDOPA. In the series
of Marzola et al., FDOPA was positive alone in 5/18
patients, but FDG was positive alone in 1 patient and
showed more lesions in 2 others [28]. In the series of
Kauhanen et al., for a CEA doubling time of less than
24 months, FDG PET/CT correctly detected metastases in
80 % of patients and FDOPA PET/CT in 60 % [29]. An
efficacy of FDG in cases of short doubling time of serum
CTN and CEA levels has been confirmed by Verbeek et al.
[30], FDG PET positivity being an indicator for poor sur-
vival, while FDOPA PET detected significantly more
lesions (56/75=75 %) than did FDG PET (35/75=47 %) in
21 patients. This relation between FDG uptake, short CTN
doubling time and progression of metastatic MTC had al-
ready been noted: of 11 patients with positive FDG PET, 6
died from metastatic disease and 4 had disease progression;
of 12 patients with negative FDG PET, 1 had recurrent
disease, and 11 had no evidence of clinical disease [31].
In 10 of the 18 patients of the Italian co-operative com-
parative study, FDOPA PET/CT identified significantly
more lesions than FDG PET/CT and SRPET/CT, whereas
in one patient FDG PET/CT revealed multiple liver lesions
missed by both FDOPA PET/CT and SRPET/CT as well as
two additional locoregional lymph nodes [32]. No addition-
al lesions were identified by SRPET/CT.
The results of another study comparing FDG and SRPET
in 18 patients with recurrent MTC are concordant:
SRPET/CT achieved disease detection in 13 of 18 patients
(72 %) and FDG PET/CT in 14 of 18 (78 %) patients; FDG
revealed a total of 28 metastatic MTC regions and SRPET
23 regions [34]. Of eight patients with occult biochemical
recurrence of MTC, FDG negative and FDOPA not per-
formed, reported by Pałyga et al., SRPET/CT localised in
two cases the recurrent cervical lymph nodes which were
confirmed after resection [35]. The same proportion (one of
four) was observed by another Polish team [36].
FDG showed a superior diagnostic performance when
compared to all SPECT radiopharmaceuticals: 123I-MIBG
[37, 38], pentavalent 99mTc-dimercaptosuccinic acid [4, 37,
39], 99m Tc-sestamibi [37] or somatostatin analogues for
SRS [37, 39–41], with the exception of the earliest study
[22]. SRS appeared to be less sensitive than conventional
imaging at detecting the full extent of metastatic disease in
11 children and adolescents with hereditary MTC [42].
In conclusion, data have been obtained mostly in cases of
rising tumour marker levels after thyroidectomy. In this
context, imaging is recommended if CTN is >150 ng/ml
[43]. FDOPA is the best tracer; an early image acquisition
starting during the first 15 min is advised [14] (Fig. 1). In
negative cases, FDG should be the next PET tracer, in
particular if CEA levels are elevated or rapidly rising [27,
29–32], and SRPETwhen neither FDOPA nor FDG PET are
contributive [34–36].
Merkel cell carcinoma
Merkel cell carcinoma (MCC) is a rare and aggressive NET
derived from cells located in the basal layers of the epider-
mis. Its clinical behaviour is characterised by aggressive
regional nodal invasion, distant metastases and a high rate
of recurrence, appearing in the majority of cases within the
first 6–12 months after initial diagnosis.
Whole-body imaging is useful to stage and restage the
tumour as well as sentinel lymph node detection for resec-
tion. The functional imaging modalities proposed for the
detection of distant lesions of MCC were, like in most
NET, 131I-MIBG SPECT [44], SRS [45] and FDG PET [46].
MCC shares similarities with both cutaneous melanoma
and small cell carcinoma of the lung, which both evidenced
uptake of FDOPA. Our team [47] observed that FDOPA
was taken up in two MCC cases and true-negative in one
suspected recurrence on SRS. However, the contrast of the
images was lower with FDOPA than with FDG. The team
in Vienna obtained similar results on 5 FDOPA PETs vs 24
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Table 1 FDOPA and comparators in MTC: comparative studies with a standard of truth











PET Se lesion based
Overall
27 lesions 17/27=63 % FDG 12/27=44 %
SRS 14/27=52 %
CT or MRI 22/27=81 %
Primary tumour/local
recurrence
2/3=66 % FDG 2/3=66 %
SRS 2/3=66 %
CT or MRI 3/3=100 %
Lymph node metastases
14/16=88 % FDG 7/16=44 %
SRS 8/16=50 %
CT or MRI 11/16=69 %
Organ metastases
1/8=13 % FDG 3/8=38 %
SRS 4/8=50 %
CT or MRI 8/8=100 %
Sp lesion based
Overall
21/22=95 % FDG 22/22=100 %
SRS 22/22=100 %
CT or MRI 18/27=67 %
Primary tumour/local
recurrence
8/8=100 % FDG 8/8=100 %
SRS 8/8=100 %
CT or MRI 6/11=55 %
Lymph node metastases
5/5=100 % FDG 5/5=100 %
SRS 5/5=100 %
CT or MRI 4/7=57 %
Organ metastases
8/9=89 % FDG 9/9=100 %
SRS 9/9=100 %
CT or MRI 8/9=89 %
Beuthien-Baumann
et al. (2007) [25]




FDG 15 patients 8/15=53 % FDG 7/15=47 %
OMFD 10 patients OMFD 1/10=10 %
Koopmans et al.
(2008) [27]
21 patients with biochemical
recurrence of MTC, 134
lesions
PET Se patient based
13/21=62 % FDG 4/17=24 %
FDG 17 patients/102 lesions DMSA-V 5/18=28 %
MRI or CT 7/18=39 %DMSA-V 18 patients/108
lesions Se lesion based
MRI or CT 18 patients/
126 lesions
95/134=71 % FDG 48/102=30 %
DMSA-V 20/
108=19 %
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FDG PETs [48]. In further series, the elective radiophar-
maceutical was FDG, with a clear utility to detect nodal
basin involvement (sensitivity=83 %, specificity=95 % for
FDG vs 0 and 86 % for MRI, respectively) [49], as well as
Table 1 (continued)






MRI or CT 80/126=64 %
For all imaging modalities





26 patients with MTC and
elevated calcitonin levels
PET/CT Se patient based
53 lesions 21/26=81 % FDG 15/26=58 %
Detection rate for malignant
lesions




Follow-up of MTC PET and PET/CT Se patient based
28 examinations, 26
patients
PET/CT 14/19=74 % CT 13/19=68 %
Sp patient based
PET/CT 9/9=100 % CT 7/9=78 %
In relation to serum calcitonin
baseline levels
< 60 ng/l → 0 TP results
>120 ng/l → 0 TN results
>150 ng/l → Se & Sp=100 %
Marzola et al.
(2010) [28]
18 patients with occult
recurrence of MTC
PET/CT Patient-based detection rate




19 patients with occult
recurrence of MTC,
118 regions
PET/CT Patient-based detection rate













13/18=72 % SRPET 6/18=33 %
FDG 3/18=17 %
Lesion-based sensitivity
61/72=85 % SRPET 14/72=20 %
FDG 20/72=28 %
Overall 156 patients Se patient based
95/136=70 % (95 %
CI 62.1–77.6)
FDG 50/113=44 %
(95 % CI 35–53.4)
Se lesion based
284/404=70 % (95 %
CI 65.8–74.8)
FDG 156/372=42 %
(95 % CI 36.9–46.9)
CI confidence interval, DMSA-V pentavalent dimercaptosuccinic acid scintigraphy and SPECT, MTC medullary thyroid cancer, OMFD 3-O-
methyl-6-[18 F]fluoro-DOPA, MD multidetector, Se sensitivity,Sp specificity, SRS somatostatin receptor scintigraphy using 111 In-pentetreotide
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distant metastases [50], performing better than SRS [51],
but with some false-negative results [52] probably in less
aggressive forms.
In conclusion, FDG should be the first-line functional
examination in MCC. When negative, it could be completed
with SRPET.
Small cell lung cancer
Being a whole-body technique, PET can play a major role for
a rapid staging of small cell lung cancer (SCLC) needed by the
urgent therapeutic decision: FDG PET has been proposed for
this purpose [53]. Since SCLC shares metabolic character-
istics with NET, we speculated that FDOPA could be useful,
being more specific than FDG and able to detect brain metas-
tases. FDOPA and FDG PETwere performed in four patients
with newly diagnosed SCLC [54]. FDOPA PETappeared less
sensitive than FDG PET and standard imaging procedures in
the staging of SCLC. The utility of FDG PET for SCLC
imaging has been confirmed in larger series [55].
In conclusion, FDG and not FDOPA is the reference
tracer in SCLC.
Bronchial carcinoids
Bronchial carcinoids (BC) are histologically classified into
typical (ca. 90 %) or atypical, with consequences on man-
agement. To the best of our knowledge, only a few cases
have been reported using FDOPA PET: one was positive
only on early images [56], and, by pooling the results of two
comparative studies [56, 57] in a total of 8 patients, the
FDOPA patient-based detection rate was 4/8 =50 % vs
7/8 =88 % for SRPETwhich showed more foci than FDOPA
in 2/4 cases.
SRPET/CTwas performed in 11 patients to stage BC; the
detection rate was 9/11 =82 %, leading to a change in
management of 3 of these 9 patients [58]. FDG uptake by
the primary BC lesion is also frequent: by pooling the
results of 4 studies, it was 36/42 =86 % [59–62]. However,
no metastatic BC was included in those series.
Very concordant results can be derived from two com-
parative studies of SRPET/CT and FDG PET/CT [63, 64], in
a total of 24 typical and 9 atypical BC: typical BC showed
higher and more selective uptake on SRPET/CT than on
FDG PET/CT, while the reverse was observed for atypical
BC and higher grades of lung NET. Diffuse idiopathic
pulmonary neuroendocrine cell hyperplasia showed no up-
take either on SRPET/CT or on FDG PET/CT. These results
are in accordance with the classification of BC into the
“foregut” group [65], with good overall results for SRS or
SRPET in cases of well-differentiated NET.
In conclusion, if BC staging is found clinically useful,
SRPET could be recommended, except in cases of atypical
BC where FDG could be recommended as first line.
Paraganglioma, phaeochromocytoma and glomus
tumour
Paragangliomas (PG) derive from the sympathetic or the
parasympathetic systems, which comprise phaeochromocyto-
mas derived from chromaffin cells in the adrenal gland, extra-
adrenal sympathetic PG and parasympathetic PG, in particular
glomus tumours and chemodectomas. The current reference
radiopharmaceutical for scintigraphy is MIBG that traces
expression of tumour-specific catecholamine transport and
storage mechanisms by phaeochromocytoma/PG cells, even
though SRS might be considered to supplement 123I-MIBG in
suspicious metastatic phaeochromocytomas [66].
Several PET radiopharmaceuticals have been proposed,
tracing the catecholamine pathway: FDOPA, its metabolite
FDA [67], and 11C-hydroxyephedrine [68, 69]. FDOPA
PET imaging of phaeochromocytoma was proposed by Hoe-
gerle et al. in 2002 [70]. FDOPA PET, 123I-MIBG scintig-
raphy and MRI were performed in 14 consecutive patients
suspected of having phaeochromocytomas [5 sporadic and 9
with von Hippel-Lindau (VHL) syndrome]. Both FDOPA
PET and MRI detected 17 phaeochromocytomas (11 soli-
tary, 3 bifocal; 14 adrenal, 3 extra-adrenal). Sensitivity was
100 % for FDOPA PET vs 71 % for 123I-MIBG scintigra-
phy, and specificity was 100 % for both procedures.
Since then, several studies have been published [17,
70–87] (Table 2) and also European Association of Nuclear
Medicine (EANM) guidelines [80]. A recent meta-analysis
of 11 studies comprising 275 patients with suspected PG
[81] found that pooled sensitivity of FDOPA PET(/CT) in
detecting PG was 91 % (patient based) and 79 % (lesion
based). The pooled specificity of FDOPA PET(/CT) was
95 % for both patient-based and lesion-based analyses.
FDOPA PET(/CT) seems to be accurate in both adrenal
[17, 70–72] or extra-adrenal [73, 75–77], sympathetic
[70–72, 74] or parasympathetic [73, 75–77], functioning
[74] or non-functioning [71, 73, 76] and metastatic or non-
metastatic PG [75, 79, 82] or VHL [70, 83, 84] PG.
When compared to 123I-MIBG [74, 77, 79], SRS [76], MRI
[73, 74] or CT [74], FDOPA had the best diagnostic perfor-
mance. In particular FDOPA is very sensitive for detecting head
and neck PG, usually derived from parasympathetic ganglia
[73, 76]. In contrast, no MIBG uptake is detected when expres-
sion of vesicular monoamine transporter 1 is lacking [77].
In the series of Charrier et al. [76], FDOPA PET detected
significantly more cervical than abdominal lesions (97 vs
67 %); in two patients with the succinate dehydrogenase sub-
unit D (SDHD) mutation, FDOPA PET missed five abdominal
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PG lesions, which were detected by the combination of
SRS, 131I-MIBG and FDG. In other studies, SDHD
mutation was associated with good FDOPA patient-
based detection rate: eight of ten [73], five of six
[77], seven of seven [78], eight of eight [84] and four
of four [82], overall 91 %.
The comparison with FDG or FDA should be performed
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mutations. In 2009 Timmers et al. published a comparative
study of 52 patients [82] using FDOPA PET, 123I-MIBG
scintigraphy, FDA PET/CT and FDG PET/CT. It should be
noted that FDOPA imaging was performed with a PET only
machine of a former generation than PET/CT used for the two
other PET tracers. In 15 patients with succinate dehydroge-
nase subunit B (SDHB) mutation, FDA and FDG had a higher
overall lesion-based sensitivity (82 and 83%) than 123I-MIBG
(57 %) and FDOPA (20 %). In 13 patients without SDHB
mutation, including 4 patients with SDHD mutation, FDOPA
had the best lesion-based sensitivity (93 %), followed by FDA
(76 %), 123I-MIBG (59 %) and FDG (62 %).
As somatostatin receptors are expressed by 73 % of
phaeochromocytomas and 93 % of PG [85], SRS is an
alternative. In the limited comparative studies, its sensitivity
was less than that of FDOPA but greater than that of 123I-
MIBG, in particular in head and neck PG [76, 78] or to
detect metastatic sites of malignant phaeochromocytoma
[66]. Concordantly, the superiority of SRPET over 123I-
MIBG SPECT to pick up head and neck PG lesions and
bone metastases has been confirmed recently in a series of
15 patients [86]. For the moment, there is no comparative
study between FDOPA and SRPET(/CT) in this context.
Concerning the impact of FDOPA PETon the management
of PG patients, the rate of change in patient management was,
in our series, 3/24 (12 %) overall and 3/15 (20 %) in proven
phaeochromocytoma, leading to pertinent decisions [87]. In
the prospective study by Fiebrich et al., FDOPA PET influ-
enced treatment decisions in 14/48 patients (29 %) [74].
In conclusion, a strategy of examinations in the diagnos-
tic workup of PG/phaeochromocytoma could be to perform
FDOPA PET/CT as first-line examination, except in patients
with clinically aggressive forms or with SDHB mutation in
whom FDG (or FDA if available) should be preferred.
Well-differentiated carcinoid tumours of the digestive
tract of a midgut origin
Endocrine tumours of the gastrointestinal tract are charac-
terised by a great heterogeneity. The midgut carcinoid, orig-
inating from enterochromaffin Kulchitsky cells in the crypts
of Lieberkühn in the small intestine, has a relatively high
tendency to metastasise via local lymph nodes to the liver; in
this context, most patients present with carcinoid syndrome,
including symptoms of flushing, diarrhoea, bronchocon-
striction and right-sided heart failure caused by overproduc-
tion of substances such as serotonin and tachykinins.
Serotonin is produced by the carcinoid tumour cells.
Concerning the performance of SPECT radiopharmaceuti-
cals, by pooling the results of two comparative series, the
patient-based detection rate was 64/71 =90 % for SRS vs
48/71 =68 % for MIBG [62, 88]. In one series aggregating
the results of carcinoid tumours of various origins, the
detection rate was also better for SRS: 67 vs 50 % for
123I-MIBG [89].
The initial case with FDOPA imaging in a NET reported by
Hoegerle et al. in 1999 [90] was a patient with metastasising
carcinoid in whom various imaging procedures were not
successful in detecting the primary tumour. Due to the
importance of primary tumour proof for potential curative
surgical therapy, FDOPA PET was performed that enabled
localisation of a potential primary tumour in the ileum.
Moreover, in addition to the known abdominal lymph node
and liver metastases, it detected a mediastinal lymph node
metastasis and a pulmonary metastasis.
Hoegerle et al. [91] subsequently demonstrated, in 16
patients with gastrointestinal carcinoid tumours, that
lesion-based sensitivity was 65 % for FDOPA PET, better
than 57 % for SRS and 29 % for FDG PET; however, the
midgut origin of all tumours was not ascertained.
Possible detection of metastatic lesions with FDG was
reported in 8/11 patients with NET of midgut or unknown
origin [92]; SRS detected NET in 10/11 patients. The de-
tection rate of FDG PET was less in another series [93]:
metastatic NET of the small intestine was visible in only one
of four cases.
In 24 patients with abdominal carcinoid tumours and bio-
chemical proof of increased serotonin metabolism, per-patient
analysis showed sensitivities of 100 % for 5-HTP, 96 % for
FDOPA, 86 % for SRS and 96 % for CT [18]. Per-lesion
analysis revealed sensitivities of 78 % for 5-HTP PET, 89 %
Fig. 1 MTC treated by total thyroidectomy and lymph node dissec-
tion. a–b The patient presented with an occult biochemical recurrence
1.5 years later [serum calcitonin (CTN)=1,130 ng/l, carcinoembryonic
antigen (CEA) =46 μg/l] and was referred to FDOPA PET/CT. On the
early images after injection (a), a clear focus was visible,
corresponding on CT to a left lymph node in the left upper mediasti-
num, with smaller and less intense contralateral foci. But the foci were
no longer visible 1 h later on the whole-body acquisition (b) and the
examination was considered as doubtful. c–e Another 1.5 years later,
the markers were still rising (CTN=2,400 ng/ml, CEA =59 μg/l) and
the patient was referred for FDG and FDOPA PET/CT prior to surgical
exploration. On FDG PET/CT, 1 h after injection, a faint uptake
(SUVmax =1.8) was visible by the left mediastinal lymph node (the
most intense FDOPA uptake 1.5 years before) (c) but no other lesion
(d). On FDOPA PET/CT (e), the left mediastinal focus took up FDOPA
(SUVmax =2.9) together with several other foci: one left supraclavicular
focus and one upper thoracic focus on the left side and two foci in the
right upper mediastinum. Their intensity decreased after 1 h. The
dissection and histological examination of the left supraclavicular
region found two metastatic lymph nodes, 8 and 5 mm in size. CTN
levels dropped to 1,600 ng/l. f Nineteen months later, another FDOPA
PET was performed for restaging prior to surgery. With the exception
of the left supraclavicular focus which had been resected, all other foci
were viable, and their uptake at 1 h was now as intense as on the early
images. This observation illustrates the importance of early image
acquisition after FDOPA injection for early detection of metastatic
MTC and the better performance of FDOPA as compared to FDG in
a slow-growing form of MTC
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Table 2 FDOPA and comparators in phaeochromocytoma and/or paraganglioma: studies with a standard of truth








14 patients with suspected
phaeo, 8 controls
PET Se patient based




17/17=100 % 123I-MIBG 10/14=71 %
Sp lesion/site based
25/25=100 % 123I-MIBG 22/22=100 %
Montravers et al.
(2008) [87]
24 patients with suspected or
recurrent phaeo






9 patients: 5 with phaeo, 4
with PG
PET/CT Se patient based





48 patients with catecholamine
excess
PET Se patient based
43/48=90 % 123I-MIBG 31/48=65 %
CT/MRI 32/48=67 %
Se lesion based




25 patients with suspected or
known phaeo
PET (11 patients) Se patient based





25 patients: 16 for detection and














53 patients with known or
suspected PG, including:
PET Se lesion based
15 with SDHB mutation Non-metastatic PG
13 without SDHB mutation 21/26=81 % 123I-MIBG 20/26=78 %
FDA PET/CT 20/26=78 %
FDG PET/CT 23/26=88 %
Metastatic PG
96/211=45 % 123I-MIBG 106/187=57 %
FDA PET/CT 161/211=76 %
FDG PET/CT 157/211=74 %
SDHB mutation
25/126=20 % 123I-MIBG 60/106=57 %
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FDA PET/CT 103/126=82 %
FDG PET/CT 105/126=83 %
Without SDHB mutation
Se 79/85=93 % 123I-MIBG 48/81=59 %
FDA PET/CT 65/85=76 %
FDG PET/CT 53/85=62 %
Fottner et al.
(2010) [77]
30 patients: PET Se patient based
24 with catecholamine excess 24/25=96 % 123I-MIBG 20/25=80 %
5 with adrenal incidentaloma SDHB mutation 2/6=33 % 123I-MIBG SDHB mutation
2/6=33 %
1 with SDHD mutation SDHD mutation 5/6=83 % 123I-MIBG SDHD mutation
3/6=50 %
Se lesion based
Se 63/64=98 % 123I-MIBG 34/64=53 %
CT/MRI Se 35/64=55 %
Sp lesion based
63/63=100 % Sp 31/34=91 %
Luster et al.
(2010) [17]
25 patients with suspected
phaeo
PET/CT Se patient based
Staging 8/8=100 %
Restaging Se 7/7=100 %
Sp patient based
Stading 2/2=100 %
Restaging Sp 7/8=88 %
Charrier et al.
(2011) [76]
25 patients with known or
suspected non-metastatic
extra-adrenal PG
PET/CT Se patient based
22/23=96 % SRS 17/23=74 %
Se lesion based
39/45=87 % SRS 23/45=51 % p<0.001
Se H&N or thoracic lesions
29/30=97 % SRS 20/30=67 %
Se abdominal lesions
10/15=67 % SRS 3/15=20 %
King et al.
(2011) [78]
10 patients with H&N PG: PET/C Se patient based
7 SDHD mutation 10/10=100 % CT/MRI 10/10=100 %
3 SDHB mutation FDG PET/CT 8/10=80 %




26/26=100 % CT/MRI 21/26=81 %
FDG PET/CT 20/26=77 %





12 patients with known
or suspected recurrent PG
PET/CT Se patient based
Se 12/12=100 % 123I-MIBG Se 9/12=75 %
Se lesion based
Overall
347/353=98 % 123I-MIBG 136/353=38 %
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for 5-HTP PET/CT, 87 % for FDOPA PET, 98 % for FDOPA
PET/CT, 49 % for SRS, 73 % for SRS SPECT/CT and 63 %
for CTalone. FDOPA detected significantly more lesions than
SRS and than 5-HTP.
This very elective FDOPA uptake by midgut NET
made it possible, in three patients, to differentiate on
PET between metastases of NET and a second primary
malignancy, an FDG-positive adenocarcinoma [94]. Meta-
chronous cancers frequently develop in patients with small
intestine carcinoid tumours (29 % according to Amin et
al. [95]) and deserve full staging and treatment. A similar
case is reported on in Fig. 3.
In a series of 77 patients with digestive NET [96], the
large majority (82 %) being of midgut origin, FDOPA
uptake on PET reflected tumour load. Patient whole-body
metabolic tumour burden determined on FDOPA PET/CT
was correlated with urinary serotonin, urinary and plasma 5-
hydroxyindoleacetic acid (5-HIAA), urinary norepineph-
rine, epinephrine, dopamine and plasma dopamine, but not
with serum chromogranin A (CgA).
Comparison with SRPET is currently only available in a
few cases. In the series of Ambrosini et al., PET/CT results
were concordant in two cases with multiple lymph node
and/or liver lesions [57], FDOPA showing more lesions in
Table 2 (continued)









62/66=94 % 123I-MIBG 39/66=59 %
Lymph nodes
25/29=86 % 123I-MIBG 18/29=62 %
Liver
25/25=100 % 123I-MIBG 18/25=72 %
Rischke et al.
(2012) [84]
101 patients with suspected
or proven phaeo or PG:
68 proven
PET/CT Se patient based
Overall
63/68=92 %
VHL mutation 17/19=89 %
SDHB mutation 10/12=83 %
SDHD mutation 8/8=100 %
Other mutation 3/3=100 %






Overall 258 patients with phaeo or PG Se patient based
89 patients without 243/258=94 % (95 %
CI 91.4–97.1)
123I-MIBG 79/115=69 %
(95 % CI 60.2–77.1)
Sp patient based
84/89=94 % (95 %
CI 87.4–98.2)
Se lesion based
700/866=81 % (95 %
CI 78.4–83.4)
123I-MIBG 314/670=47 %
(95 % CI 43.1–50.7)
Sp lesion based
Sp 88/88=100 % (95 %
CI 95.9–100)
123I-MIBG 53/56=95 %
(95 % CI 85.1–98.9)
CI confidence interval, FDA 18 F-fluorodopamine, H&N head and neck, phaeo phaeochromocytoma, PG paraganglioma, SDHB succinate
dehydrogenase subunit B, SDHD succinate dehydrogenase subunit D, Se sensitivity (or patient-based detection rate when all patients are diseased).
Sp specificity, SRS somatostatin receptor scintigraphy using 111 In-pentetreotide, VHL von Hippel-Lindau
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one case and SRPET in the other one. In the series of Haug
et al., four NET in patients with serotonin levels >700 ng/ml
originated from the ileum, and all were FDOPA positive and
SRPET positive [97]. An interim analysis of the on-site
readings of a prospective study that we are currently
performing demonstrated that, in 14 patients with a carci-
noid tumour of the ileum, the patient-based sensitivity was
100 % for both FDOPA PET/CT and SRPET/CT but
FDOPA showed more uptake foci in 8/14=44 % of patients
[98]. In summary, in all 20 patients, both tracers were able to
detect lesions of midgut carcinoid NET, FDOPA showing
more lesions in 9/20= 45 % of patients and SRPET in 1/20=
5 % of patients.
The rate of change in management was 50 % in our series
of 22 patients with histologically documented carcinoid
tumour of the ileum, relevant in all cases according to
follow-up data [21]. In the series of 16 digestive carcinoid
tumours of Hoegerle et al. [91], FDOPA PET resulted in
a b
Fig. 2 Right block of images FDOPA PET/CT: anterior and left lateral
maximum intensity projection, transverse slice. Left block
corresponding FDG PET/CT images. FDOPA PET/CT was performed
for characterising a left adrenal tumour (dashed arrow) discovered
incidentally on FDG PET/CT performed for staging a squamous cell
carcinoma of the anal canal (full arrow) in an asymptomatic patient. As
the adrenal tumour took up both FDOPA and FDG, it was interpreted
as an aggressive phaeochromocytoma. This was confirmed on histo-
logical examination. This observation illustrates the increase in speci-
ficity brought by FDOPA for characterising NET
a b
Fig. 3 a–b In a haemodialysed patient candidate for renal grafting,
systematic CT discovered a tumour of the terminal ileum evocative of a
carcinoid origin with mesenteric locoregional adenopathies, the largest
being 35 mm in size. Biopsy of a right iliac adenopathy confirmed a
metastatic well-differentiated NET (Ki-67<1 %). FDOPA PET/CT
performed for staging showed the primary carcinoid tumour in the
terminal ileum (a dotted arrow) and large lymphadenopathy with two
satellite lymph nodes (a black arrows), but also a focus in the upper left
abdomen, SUVmax =4.7 (a, b green arrow) corresponding on CT to a
dense content in a renal cyst. c FDG PET/CT was performed to better
characterise the renal anomaly that took up FDG (c green arrow on the
transverse slice) with a somewhat lower intensity than FDOPA
(SUVmax = 3.9). As expected, the metastatic carcinoid tumour in the
right abdomen did not take up FDG (c). Thus the renal cystic lesion
was probably not of a carcinoid origin. A CT-guided biopsy of the
renal lesion was performed and histology revealed a renal carcinoma.
This observation illustrates the ability of FDOPA to detect carcinoid
tumours with low aggressiveness, but also renal carcinomas, and the
synergy between FDOPA and FDG PET/CT
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modification or even complete change in therapeutic strate-
gy in 31 % of cases.
In conclusion, using FDOPA PET/CT as the first-line func-
tional imaging modality for the management of digestive NET
originating from midgut allows small lesions to be detected
and corresponds to its MA [18, 20, 91, 99] (Table 3). FDOPA
imaging induced relevant changes in patient management [21,
91]. Its superiority over SRS has been confirmed by several
teams. SRPET appears to be a competitor, although it showed
less foci in some patients; dedicated comparative studies are
currently lacking. With FDG PET, very limited results have
been reported in midgut NET [91–93]; FDG is able to show
some metastatic lesions of intestinal NET, but a significant
FDG uptake in this context should also be a warning sign of a
metachronous “common” cancer [94].
Neuroendocrine tumours of the digestive tract of hindgut
origin (transverse and left colon and rectum)
Hindgut carcinoids metastasise in about 3–5 % of cases and
rarely present hormonal symptoms or elevation of urinary-5-
HIAA despite the content of peptides and hormones. Glob-
ally, these NET are more aggressive and more often poorly
differentiated than NET originating from midgut [100].
To the best of our knowledge, no study with FDOPA has
been reported in this NET; only two FDOPA-positive SRS-
positive cases were reported in the series of Hogerle et al.
[90] and three FDOPA-negative SRPET-positive cases in
patients with serotonin levels <200 ng/ml in the series of
Haug et al. [97]. The patient-based detection rate was 5/6 for
FDG vs 4/6 with SRS in the study of Binderup et al. [62]
and 5/6 with SRS in the study of Ezziddin et al. [88], MIBG
being ineffective in both series (2/12=17 %). Case reports
describe FDG imaging and treatment monitoring in aggres-
sive metastatic NET, also referred to as small cell colorectal
cancer [101, 102].
In conclusion, in cases of NET tumours of the rectum or
the transverse and left colon, FDG and/or SRPET are able to
localise the lesions, even if evidence is currently limited
about the impact of the examination.
Endocrine pancreatic tumours (except hyperinsulinism
in infants), NET of the stomach or the duodenum
Endocrine pancreatic tumours (EPT) are part of foregut
NET and include insulinomas, gastrinomas, VIPomas, glu-
cagonomas, somatostatinomas and non-functioning NET.
In malignant tumours, mixed syndromes are common due
to multiple hormone production from the tumours. In
about one third of EPT, the patients present no hormonal
symptoms, bearing a non-functioning NET. EPT can also
be part of type I multiple endocrine neoplasia (MEN-I)
syndrome, in which multiple pancreatic tumours are al-
most always found. Concerning the performance of
SPECT radiopharmaceuticals, by pooling the results of 3
comparative series, the patient-based detection rate was
47/52 =90 % for SRS vs 17/52 =33 % for MIBG [62,
88, 89].
Only 11/22=50 % of the EPT could be detected with
11C-L-DOPA; in 2 additional patients, CT enabled detec-
tion of tumours not detected on PET [103]. We reported
concordant results with FDOPA in 10 EPT [20]: poor
patient-based sensitivity of 2/8=25 %, contrasting with a
better sensitivity of SRS: 6/8=75 %. Concerning other
radiopharmaceuticals for SPECT, by pooling the results
of 3 comparative series in EPT, MIBG had a low patient-
based detection rate of 11/52= 21 % vs 47/52 =90 % for
SRS [62, 88, 89]. 111In-glucagon-like peptide 1 (GLP-1)
receptor scintigraphy has been proposed specifically for
insulinoma [104].
The article of Koopmans et al. in 2008 [18] included 23
patients with pancreatic islet cell tumours; 39 % of patients
had biochemical proof of increased serotonin metabolism.
Patient-based sensitivity was 100 % for 5-HTP PET, 89 %
for FDOPA PET, 78 % for SRS and 87 % for CT. Per-lesion
analysis revealed sensitivities of 67 % for 5-HTP PET, 96 %
for 5-HTP PET/CT, 41 % for FDOPA PET, 80 % for
FDOPA PET/CT, 46 % for SRS, 77 % for SRS SPECT/CT
and 68 % for CT alone. Although 5-HTP PET/CT was
superior to FDOPA PET/CT in islet cell tumours, 11C-5-
HTP cannot be produced and delivered for routine use as
easily as FDOPA. In contrast with our results, FDOPA
PET/CT had better sensitivity than SRS, even performed
with SPECT/CT fusion.
Insulinoma may constitute an indication for FDOPA, as the
sensitivity of SRS has been reported to be limited. Currently,
only small series have been reported. The detection rate was
9/10=90 % in the series of Kauhanen et al. [105], but another
preliminary study reported a poor detection rate [106]: in 5
adults with hyperinsulinism, no tumour was detected with
FDOPA while CT was positive in 4 cases; the only FDOPA
detection occurred in 1 child with multiple NET MEN-I.
FDOPA PET was compared with SRPET in very small
series. Its performance was equal to that of 68Ga-DOTATOC
in four EPTs reported by Putzer et al. [107]. In the series of
Ambrosini et al., the per-patient detection rate was 5/8 for
FDOPA vs 8/8 for 68Ga-DOTANOC [57] which showed
more foci in 4 of the 5 FDOPA-positive patients. In another
series of five EPTs, FDOPA was positive in three cases
whereas SRPET was positive in all cases [97]. Since
FDOPA has a limited sensitivity for most types of EPT
and a good one for midgut digestive NET, in series mixing
several types of NET, its overall sensitivity and the result of
comparison with SRPET depend on the relative proportions
of those different types of NET.
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Table 3 FDOPA and comparators in digestive carcinoid tumours: studies with a standard of truth










11/16=69 % SRS 13/16=81 %
















60/92=65 % SRS 52/92=57 %
FDG 29/92=27 %
CT/MRI 91/92=99 %












PET 322/371=87 % 5-HTP 288/371=78 %




FDOPA & 5-HTP detected








FDOPA 13/14=93 % SRS 11/14=78 %
Sp patient based
FDOPA 3/4=75 % SRS 2/3=67 %
Yakemchuk et al.
(2012) [99]
18 patients with midgut
carcinoid tumour
Se patient based
189 sites 20/21=95 % SRS 19/21=90 %
183 lesions CT 19/21
Se site based
53/56=95 % SRS 34/56=61 %
CT 37/56=66 %
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No series have been identified concerning stomach or
duodenal NET, also part of foregut digestive NETs, and
only a few cases in larger series: patient-based sensitivity
of 1/4=25 % for FDOPA vs 3/5=75 % for SRS [20] or of
2/4=50 % for FDOPA vs 3/4=75 % with SRPET (pooling
results of studies [57], [97] and [107]), SR-based imaging
usually showing more foci.
In the case of an aggressive form of well-differentiated
NET with Ki-67 >10 %, the first-line tracer should be FDG:
in 18 patients (15 with foregut NET), FDG patient-based
sensitivity was 100 % vs 83 % for SRS, and FDG PET
detected more lesions than SRS in 78 % of cases [108].
When no selection was made on Ki-67 value, the detection
rate in 29 patients was 79 % for FDG and less than 90 % for
SRS [62].
In conclusion, in cases of differentiated EPT, SRPET is
the first-line examination, except if Ki-67 >10 % favours
FDG PET. If negative, FDOPA can be useful, in particular in
gastric or duodenal NET as well as in some cases of positive
SRPET or FDG PET when there is a doubt about the nature
of a positive focus: FDOPA is more tumour specific than the
somatostatin analogues or FDG which are taken up by
leucocytes in inflammatory lesions.
Congenital hyperinsulinism in infants
Although insulinoma, a digestive NET generally of a benign
nature, induces hyperinsulinism, congenital hyperinsulinism
(CHI) is a specific clinical setting, as clustered beta-cell
hyperplasia is found in the resectable cases, rather than a
definite tumour. Although this indication does not strictly
belong to oncology, the excellent performance of FDOPA
will be briefly summarised.
In infants with CHI, which results in life-threatening hypo-
glycaemia, the aim of imaging is to localise focal hyperplasia
Table 3 (continued)




FDOPA vs SRS and/or
CT, p<0.001
Se lesion based
175/183=96 % SRS 92/183=50 %
CT 126/183=69 %
FDOPA vs SRS and/or
CT, p<0.001
Sp site based
132/132=100 % SRS 132/133=99 %
CT 132/135=98 %
2/21=10 % major impact
on patient management
10/21=48 % minor impact
on patient management
Overall 76 patients Se patient based
68/76=89 % (95 %
CI 80.3–95.3)
SRS 60/75=80 %
(95 % CI 69.2–88.4)
CT/MRI 54/61=89 %
(95 % C: 77.8–95.3)
Se site based
113/148=76 % (95 %
CI 76.3–83.2)
SRS 86/148=58 %
(95 % CI 50.2–66.0)
CT/MRI 128/148=86 %
(95 % CI 81–92)
Se lesion based
539/554=97 %
(95 % CI 96.0–98.6)
SRS 274/554=49 %
(95 % CI 45.3–53.7)
CT/MRI 360/554=65 %
(95 % C: 61–69)
LN lymph node, 5-HTP 11 C-5-hydroxytryptophan PET, CI confidence interval, Se sensitivity,Sp specificity, SRS somatostatin receptor scintigraphy
using 111 In-pentetreotide
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of beta cells in the pancreas: hyperinsulinism with focal lesion
(s) can revert by selective surgical resection, in contrast to the
diffuse form, which requires subtotal pancreatectomy when
resistant to medical treatment.
In the initial study by Ribeiro et al. on 15 CHI children
(aged 1–14 months) [11], FDOPA PET showed an abnormal
focal pancreatic uptake in 5 patients who then underwent a
limited pancreatic resection that was followed by a complete
clinical remission. A diffuse pancreatic uptake was observed
in ten patients, four of whom underwent surgical resection
that confirmed FDOPA PET results: the abnormal beta cells
were gathered in small clusters, scattered in the whole
pancreas. In contrast, MRI performed in six infants showed
no anomaly.
These very promising results were confirmed in larger
series by the same team and by many others [109–114]
(Fig. 4). In a recent German study [114], FDOPA PET/CT
with multiphase contrast media protocols was performed in
135 CHI patients. All the foci were excised on the basis of
FDOPA PET/CT images and 87–91 % of the operated
patients could be completely healed.
Two meta-analyses have been recently published. An
Italian team concluded that the pooled sensitivity and
specificity of FDOPA PET(/CT) in differentiating between
focal and diffuse CHI were 89 and 98 %, respectively
[115]. An American team aimed to compare the diagnostic
performance of FDOPA PET, pancreatic venous sampling
(PVS) and selective pancreatic arterial calcium stimulation
with hepatic venous sampling (ASVS) in diagnosing and
localising focal CHI [116]. FDOPA PET was superior in
distinguishing focal from diffuse CHI [summary diagnos-
tic odds ratio (SDOR)= 73.2], compared to PVS (SDOR=
23.5) and ASVS (SDOR= 4.3). Furthermore, it localised
focal CHI in the pancreas more accurately than PVS and
ASVS (pooled accuracy 82 vs 76 and 64 %, respectively).
In conclusion, the results of recently published large
series are in accordance with the initial ones: FDOPA PET
(/CT) is of major utility to select those infants for surgery
and shortens the intervention by guiding the surgical explo-
ration of the pancreas.
“Carcinoids” or “endocrine small cell” or “oat cell”
tumours of other organs
Carcinoid tumours can be observed in several others organs.
Probably due to the urinary excretion of radiopharmaceut-
icals, their use seems limited in NET of the kidney or the
urinary bladder to detection and treatment follow-up of
metastases, as reported by Iagaru et al. using FDG PET
[117]. The published case reports with nuclear imaging are
focused on two sites, thymus and prostate, but none reported
the use of FDOPA.
In summary, thymic NETs are aggressive and diagnosed
at an advanced stage. FDG was able to accurately stage one
patient with lymph node and bone metastases, which were
not visible either on MIBG or on bone scintigraphies [118],
and to restage a recurrent thymic NET with multiple bone
metastases which were not visible on bone scintigraphy
[119]. In contrast, SRPET did not show any thymic NET
in the four cases of another series [120]. These preliminary
results seem somewhat discrepant with a foregut origin
currently accepted for thymus NET.
Small cell carcinoma of the prostate (SCCP) is very
aggressive, metastasises early and does not respond to most
chemotherapy regimens. In approximately 50 % of cases of
prostate cancer, tumours are a combination of small cell
carcinoma and androgen-sensitive adenocarcinoma. Our
team performed FDOPA PET in four patients that did not
show the NET contingent of the prostate cancer which was
Fig. 4 FDOPA PET/CT:
maximum intensity projection,
transverse slice and coronal
slice. Search for focal
hyperplasia of pancreatic beta
cells in an infant with
hyperinsulinism. FDOPA PET/
CT localised a focus in the tail




and the infant became
euglycaemic
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either demonstrated at histological examination (one case
taking up FDG) or suspected on high serum levels of CgA.
In 2002, Spieth et al. [121] reported in one SCCP patient
that SRS was more sensitive than bone scintigraphy to
detect metastatic foci. More recently, the use of FDG PET
has been reported in case reports for detecting SCCP
[122–124] and monitoring therapy [125].
In conclusion, in those aggressive NETs, FDG PET/CT
seems to be the best first-line examination.
Detection of unknown primary NET: NET metastases
of unknown origin, ectopic hormone secretion, or suspicion
of NETor of MEN
Concerning NET metastases of unknown origin (“CUP-
NET”), the localisation of the primary tumour is important
to optimise patient management [126]. The choice of the
best tracer depends on the most probable primary tumour
and on its aggressiveness. As FDG was superior to SRS to
detect metastatic NET, in correlation with Ki-67 [127], FDG
could be tried first in CUP-NET if Ki-67 is >10 %. High
levels of a biochemical marker may provide guidance: se-
rotonin or urinary 5-HIAA or catecholamine derivates or
calcitonin favour using FDOPA [96, 97]. Immunohisto-
chemistry may also help. The presence of CDX-2 in metas-
tases had a specificity of 100 % and a sensitivity of 40 % for
a midgut primary NET, favouring FDOPA imaging [128].
The presence of Islet 1 in metastases had a specificity of
100 % and a sensitivity of 78 % for a primary EPT [128].
PDX-1 was positive in five of five cases of metastatic
pancreatic NET and two of two cases of metastatic duodenal
NET [129] and TTF-1 was expressed almost only in bron-
chopulmonary NET [128, 129]. Thus, the presence of those
markers favours SRPET. Other markers for immunochem-
istry of NET have already been described and more will
come in future.
As early as 1999, Hoegerle et al. reported a CUP-NET
case and the successful delineation of the primary carcinoid
tumour with FDOPA PET [90]. Our team reported detection
of the primary tumour with FDOPA in 6 of 16 CUP-NET
(38 %); in 5 other patients, FDOPA PET upstaged the
disease but did not reveal a subsequently confirmed primary
NET [21].
Series have also been reported using SRPET. The detec-
tion rate of primary tumour was 5/14 [36], 4/4 [97], 3/4
[130], 35/59 [131] and 12/20 [132], overall 59/101=58 %.
SRPET could be compared with FDOPA in 4 such patients
reported by Haug et al. in 2009 [97]: in 2/4 patients,
“FDOPA PET allowed better delineation of the primary
tumour, and gave evidence of more metastases, mainly due
to higher tumour/non-tumour contrast, which was especially
seen in the liver”.
Concerning ectopic hormone secretion, PET has been
reported in cases of adrenocorticotropic hormone (ACTH)
production, which is generally due to lung or carcinoid
tumours. In one case, FDOPA successfully detected a BC
[56] and in another case a carcinoid of the appendix [133].
In another case, CT demonstrated prominent lymph nodes in
the left lung hilum and hyperplastic adrenals but no primary
tumour, SRPET/CT was non-contributive, but FDOPA
PET/CT localised the metastatic BC [134].
In our centre, eight FDOPA PET/CTs were performed in
this setting and two were positive; surgery was performed in
one of them, in view of concordance with positive FDG
PET/CT, and a thoracic NET was confirmed.
Other cases have been reported using either FDG, the
primary NET being a recurrent thymic carcinoid tumour
[135], an atypical thymic carcinoid tumour [136] or a he-
patic carcinoid tumour [137], or 5-HTP, the primary NET
being BC [138], or SRPET that detected a NET of the ileum
[139] and a NET in the right sphenoidal sinus [140].
One series of 41 patients has been reported by Zemskova
et al. but several imaging modalities were used, not in all
patients, with intervals of several months, PET being per-
formed as a second-line examination when others were not
conclusive; so, performance of modalities cannot be com-
pared [141]. Patient-based sensitivity was overall
6/13=46 % for FDOPA PET and 7/14=50 % for FDG
PET; an important point was the remarkable specificity of
FDOPA, in contrast to CT, MRI, SRS and FDG, leading to a
very high positive predictive value (PPV). FDOPA PET
improved PPV of CT/MRI, while FDG PET did not.
Concerning the localisation of parathyroid adenoma in
the case of high serum levels of parathyroid hormone,
FDOPA PET was negative in all eight patients reported by
Lange-Nolde et al. [142] and could not compete with ultra-
sonography or with 99mTc-sestamibi scintigraphy. We share
the same experience and parathyroid adenomas did not take
up FDOPA when present in patients with MEN1.
MEN1 consists of benign or malignant tumours derived
from at least two of the following cell types: parathyroid
cells, gastrin cells or prolactin-producing pituitary cells. The
same negative result was reported with SRPET/CT: of three
parathyroid gland adenomas, two were detected by CT only
and one remained totally undetected by hybrid imaging
[143]. However, in this study, SRPET/CT was able to detect
other tumours in 19 patients referred for a MEN1 syndrome,
lesion-based sensitivity was 92 % and specificity 93.5 %.
Not only 60 NET lesions were detected but also 31 benign
MEN-associated lesions. A change in management was
induced in 9/19=47 % of patients.
MEN2 associates as the main NET tumours MTC and
phaeochromocytoma the detection of which has already been
discussed above. FDA [144] or FDOPA could be favoured, as
FDG is of little help. In a series, FDG PET could not identify
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MTC foci within the thyroid in 14 MEN2A patients, but
identified 2 true-positive and 1 false-positive lymph node
metastases [145]. In another series, none of the six patients
with MEN2A syndrome had a positive FDG PET/CT for
MTC [146].
Concerning the detection of NET when only suspected,
some data are available in cases of evocative clinical symp-
toms, or of biological suspicion based on tumour marker
levels or of a suspected NET on imaging.
In a comparative study of FDOPA PET/CT and SRS in
61 patients, FDOPA PET/CT correctly identified 32 of 36
patients who actually had a NET, with a sensitivity of 91 %,
significantly greater than that of SRS (59 %), and a speci-
ficity of 96 vs 86 % for SRS [147]. In 16/61=26 % of the
patients, the management was altered as a result of new
findings on FDOPA PET/CT.
In a subgroup of 13 patients with suspected NET from a
larger series, SRPET had a sensitivity of 4/4=100 % vs.
2/4=50 % for SRS, the specificity being 8/9=89 % for both
modalities [148]. In a larger series, 70 patients were examined
by SRPET/CT primarily because of the clinical suspicion of
NET on the basis of symptoms such as persistent diarrhoea or
flushing, 49 patients because of elevated levels of tumour
markers and 53 patients because of a mass suggestive of
NET [149]. Only one third of the patients included in the
study group proved to have a NET, the most frequent local-
isation of which was the small bowel (10/36=28 %); patient-
based sensitivity was 81 % and specificity 90 %. No conclu-
sion can be drawn from the somewhat better sensitivity of
FDOPA PET/CT (91 %) [147] vs SRPET/CT (81 %) [149] as
those two studies, of a similar sample size, were not compar-
ative; the relatively high frequency of small bowel NET in this
setting is concordant with a good performance of FDOPA.
An interesting point is the high proportion of unconfirmed
suspicion of NET in the three studies (overall 102/178=57 %).
This can be explained by the lack of specificity of the clinical
signs or of the aspect of the tumour on conventional imaging;
but a selection based on chromogranin-A or on neuron-specific
enolase (NSE) serum levels was not more effective: NET was
confirmed only in 16/49=33 % of such cases in the series of
Haug et al. [149] . Of the 43 patients with elevated levels of
chromogranin-A, just 12 (29%) had histologically provenNET
and the diagnostic performance of SRPETwas not better in this
subgroup of patients. According to our experience, patients are
too frequently referred for a sophisticated imaging examination
due to a non-specific rise in chromogranin-A levels in relation
to proton pump inhibitor treatment [150]. Short-term proton
pump inhibitor use (7 days only) results in a significant increase
of chromogranin-A levels; proton pump inhibitors need to be
discontinued for 2 weeks to fully eliminate their effect on
chromogranin-A levels [151]. A simpler alternative is to assay
markers which are not affected by this very frequent treatment
in patients with digestive disorders; pancreastatin has recently
been proposed [152]. Concerning NSE, not all clinicians are
aware of the importance of processing the blood sample: hae-
molysis or conservation at room temperature result in mean-
ingless high results [153].
In conclusion, FDOPA, FDG and SRPET/CT can detect
the primary NET in a significant number of patients with
metastatic NET. The sequence of those examinations will be
guided by physical signs, serum markers, immunochemistry
and also the availability of the tracers at the PET centre.
FDOPA and SRPET/CT can detect suspected primary NET,
serum markers being useful to choose the first-line exami-
nation when both are available, associated infection or in-
flammation favouring FDOPA. Causes of a non-specific rise
in tumour marker serum levels should be considered and
ruled out.
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